<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2022.899722</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of pulsed field ablation on solid tumor cells and microenvironment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yujue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1948965"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jiang</surname>
<given-names>Tian&#x2019;an</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/772963"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Liting</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Huiyang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1665689"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1117940"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fang</surname>
<given-names>Chengyu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Ultrasound Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Key Laboratory of Pulsed Power Translational Medicine of Zhejiang Province</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Zhejiang University Cancer Center</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Min Xue, University of California, Riverside, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Yajun Zhao, Nanjing Tech University, China; Zhili Guo, Quantum-Si, Inc., United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Tian&#x2019;an Jiang, <email xlink:href="mailto:tiananjiang@zju.edu.cn">tiananjiang@zju.edu.cn</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>08</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>12</volume>
<elocation-id>899722</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>03</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>07</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Wang, Jiang, Xie, Wang, Zhao, Xu and Fang</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wang, Jiang, Xie, Wang, Zhao, Xu and Fang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Pulsed field ablation can increase membrane permeability and is an emerging non-thermal ablation. While ablating tumor tissues, electrical pulses not only act on the membrane structure of cells to cause irreversible electroporation, but also convert tumors into an immune active state, increase the permeability of microvessels, inhibit the proliferation of pathological blood vessels, and soften the extracellular matrix thereby inhibiting infiltrative tumor growth. Electrical pulses can alter the tumor microenvironment, making the inhibitory effect on the tumor not limited to short-term killing, but mobilizing the collective immune system to inhibit tumor growth and invasion together.</p>
</abstract>
<kwd-group>
<kwd>pulsed field ablation</kwd>
<kwd>irreversible electroporation</kwd>
<kwd>nanosecond pulsed electric fields</kwd>
<kwd>immunogenic cell death</kwd>
<kwd>microenvironment</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="93"/>
<page-count count="15"/>
<word-count count="8227"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>The cells demonstrate atypia as they go from normal to malignant cells, including pleomorphism, hyperchromasia, and an increase in mitotic figure. The tumor tissues also show atypia, that is, the arrangement of tumor cells becomes disordered and irregular. Changes in the tumor microenvironment have gotten a lot of attention in recent years when it comes to the occurrence and progression of cancer. The tumor microenvironment, including tumor chemical environment, immune cells, extracellular matrix (ECM), and tumor vascular system, is the tiny environment in which tumors live (<xref ref-type="bibr" rid="B1">1</xref>). The enhancement of tumor proliferation signal, the resistance of apoptosis, avoidance of immunity, and promotion of tumor microvascular formation are all related to the microenvironment (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>As an emerging ablation technique, irreversible electroporation (IRE) has the advantages of good tissue selectivity, clear ablation limits, no influence of large vessel heat sink effect, short ablation time, and few postoperative complications (<xref ref-type="bibr" rid="B3">3</xref>). Pulsed field ablation is different from traditional thermal ablation techniques such as radiofrequency ablation, microwave ablation, high intensity focused ultrasound therapy, etc. It is a heat-independent ablation with a delayed release of transient high-voltage electrical pulses that cause damage to the membrane structure of cells within the target ablation foci. The release of electrical pulses to tissues or cells can cause reversible or irreversible perforation of cell membranes, and apoptosis can be observed. There are several ablation techniques that perforate cells by electrical pulses to induce apoptosis, which can be classified according to the characteristics of the pulsed electric field parameters: nanosecond pulsed electric fields (nsPEF) deliver electrical pulses with very short pulse widths (in the range of 10-300 ns) and strong field strengths (20-150 kV/cm), and all pores remain small. IRE&#x2019;s pulse widths range from microseconds to milliseconds but its amplitudes are less than 10 kV/cm, causing a wide range of pore size variations (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). High-frequency irreversible electroporation (H-FIRE) systems that split the ~100 &#x3bc;s monopolar pulse into a series of shorter duration ~1 &#x3bc;s alternating polarity pulses (<xref ref-type="bibr" rid="B6">6</xref>). There is also electrochemotherapy (ECT), which allows the uptake of drugs by reversible electroporation (<xref ref-type="bibr" rid="B2">2</xref>). Despite the different pulse parameters, IRE, nsPEF, and H-FIRE can all act through irreversible damage to the cell membrane (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Studies have shown the safety and efficacy of pulsed field ablation (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). Pulsed field ablation can form perforations in the membrane and induce a complex immune process that alters the local microenvironment of the tumor (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). In this review, we summarize changes in tumor cells, immunogenic effects, vascularity, extracellular matrix, and chemical environment induced by electric pulses.</p>
</sec>
<sec id="s2">
<title>Changes in tumor cells</title>
<sec id="s2_1">
<title>Cell signal pathway</title>
<p>After delivering high-voltage electric pulses to tumor cells, it kills them <italic>via</italic> a variety of mechanisms including cell membrane perforation, mitochondrial damage, reactive oxygen species (ROS), and DNA damage (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). Firstly, IRE, nsPEF, and H-FIRE all cause damage to cell membranes, resulting in osmotic imbalance and cell swelling (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). And electrical pulses can also lead to DNA damage, but whether the direct effect or the indirect effect induced by apoptosis is not clear (<xref ref-type="bibr" rid="B16">16</xref>&#x2013;<xref ref-type="bibr" rid="B18">18</xref>). ROS is also one of the mechanisms of damage. High levels of ROS were found after PEF treated melanoma cells (<xref ref-type="bibr" rid="B19">19</xref>). What needs to be emphasized is that mitochondrial damage is more studied in nsPEF, because nsPEF has shorter pulse width, increasing the possibility of causing damage to organelles, and nsPEF causes mitochondrial damage by the loss of mitochondrial membrane potential (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B20">20</xref>). Thus, damage to cells through different mechanisms may lead to changes in cellular signaling pathways.</p>
<p>Some articles have focused on the effects of electrical pulses on cellular signaling pathways. According to one study, applying nsPEF to the human pancreatic carcinoma cell line (PANC-1) can change the protein expression of the Wnt/&#x3b2;-catenin signaling pathway, matrix metalloproteinases (MMP) family, and vascular endothelial growth factor (VEGF). The downstream signals of the Wnt/&#x3b2;-catenin signaling pathway, including hDPR1, &#x3b2;-catenin, and c-Myc, are dose-dependently decreased by nanosecond pulses (<xref ref-type="bibr" rid="B21">21</xref>). Wnt/&#x3b2;-Catenin has two pathways, the canonical pathway and the non-canonical, and the canonical pathway can lead to the transcription of target genes such as myc and cyclin D1, nanosecond pulses inhibit the transcription of target genes through this pathway, thereby inhibiting the proliferation of tumor cells (<xref ref-type="bibr" rid="B22">22</xref>). In addition to Wnt/&#x3b2;-catenin pathway, the expression of NF-&#x3ba;B pathway proteins including IKK-&#x3b1;, IKK-&#x3b2;, I&#x3ba;B-&#x3b1;, NF-&#x3ba;B p-65, and p-p65 is also significantly reduced (<xref ref-type="bibr" rid="B21">21</xref>). Not only that, the expression of proapoptotic lymphocytes/leukemia-2 (Bcl-2) family proteins (Bax, Bim, and BID) is promoted, and the expression of antiapoptotic Bcl-2 family proteins phosphorylated Bcl-2 protein (p-Bcl-2), Bcl-xL and myeloid leukemia-1 (Mcl-1) are inhibited (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). The MMPs family and VEGF are also lower than those of the control group. Downgrading of MMPs and VEGF can inhibit tumor invasion and metastasis. It is explained in detail in &#x201c;4. Vascularity, stroma and chemical environment &#x201c;.</p>
<p>Sun S et&#xa0;al. performed IRE on human pancreatic cancer cell line AsPC-1 and BxPC-3 <italic>in vitro</italic> and found that&#xa0;IRE&#xa0;can trigger ROS-dependent&#xa0;apoptosis&#xa0;in&#xa0;pancreatic cancer&#xa0;through the PI3K/Akt pathway (<xref ref-type="bibr" rid="B11">11</xref>). Another study found that the gene expression of KRAS and EGFR pathway signaling molecules changed significantly after IRE treatment on pancreatic tumors. EGFR signaling was inhibited: (i) causing a decrease in AKT, NF-kB, and VEGF expression, which inhibited tumor growth and invasion, metastasis, etc. (ii) leading to the inhibition of JAK and STAT3, thus providing inhibition of G0 to G1 phase transformation and reducing tumor cell replication. While K-RAS was inhibited, MEK1/2, JNK, and ERK1/2 expression were down-regulated, thus inhibiting cell replication and proliferation. IRE significantly altered the cancer hallmarks and immunosuppressive biological pathways in the PDX pancreatic tumor model. And necrosis, regeneration/repair, and inflammatory signaling were significantly increased after IRE (<xref ref-type="bibr" rid="B23">23</xref>).</p>
<p>Wnt/&#x3b2;-Catenin, KRAS, EGFR, as well as downstream cellular pathways like MMP and VEGF were found to be downregulated after electrical pulses were applied to pancreatic cancer, and then cancer biology, including proliferation, cell death, invasion, and metastasis, all changed (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>). Both IRE and nsPEF can exert anti-tumor effects by inhibiting cell replication, increasing the expression of pro-apoptotic proteins and suppressing the expression of antiapoptosis proteins, but there is not enough evidence to prove a significant difference between IRE and nsPEF in causing changes in cellular pathways.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Effect of pulsed field ablation on cell signal pathway.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-899722-g001.tif"/>
</fig>
</sec>
<sec id="s2_2">
<title>Cell death</title>
<p>Pulsed electric field ablation is known for its ability to cause apoptosis-a kind of programmed cell death. Because pro-apoptotic and anti-apoptotic factors regulate cell apoptosis, the increase in Bax, Bim, and BID and decrease in p-Bcl-2, Bcl-XL, and McL-1 after an electric pulse suggests that electroporation can promote cell apoptosis (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B26">26</xref>). Significantly increased cleavaged and active caspase 3, 7, and 9 were also detected after IRE (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B29">29</xref>), which are the markers of apoptosis. Cells exhibit the pathological characteristics of apoptosis after electrical impulses: nuclear pyknosis, nucleolysis, nuclear fragmentation, and apoptotic bodies were observed (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B30">30</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>).</p>
<p>However, during the delivery of electrical pulses, some heat will inevitably be generated. Tissues and cells exhibit distinct death features depending on their distance from the electrode needle. Generally speaking, the closer to the needle track, the easier it is to necrosis, the middle part shows irreversible electroporation, and the cells far away from the needle track are easy to form reversible perforation, which may be related to temperature, the closer the needle track is to the more heated the tissue, the more serious the thermal damage caused, which is characterized by zones of white coagulation (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B34">34</xref>). The necrosis zone shows endoplasmic reticulum and nuclear membrane expansion and random DNA degradation (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>Pyroptosis and necroptosis belong to immunogenic cell death (ICD) that rely on the release of damage associated molecular patterns (DAMPs) to drive local immune responses. Pyroptosis forms intracellular inflammatory vesicles and activates caspase-1, gasdermin D (GSDMD) channels are formed on the cell surface and interleukin (IL)-1&#x3b2;, IL-18, and DAMP molecules are released from the cell <italic>via</italic> GSDMD pores, where they stimulate an immune response. Water and ion can also influx the cell from GSDMD, causing edema of the cell (<xref ref-type="bibr" rid="B4">4</xref>). Activation of caspase-1 and GSDMD was observed in rat liver tissue at 6 and 24 hours after electroporation, illustrating that IRE can cause pyroptosis (<xref ref-type="bibr" rid="B16">16</xref>). Necroptosis is initiated by the necrosome and activates the receptor interacting serine/threonine kinase 3 (RIPK3), which activates mixed lineage kinase domain-like pseudokinase (MLKL). Activated MLKL molecules aggregate and form pores in the cell membrane, allowing the release of DAMPs and the influx of water and ions, causing cellular edema and cell membrane disintegration, similar to the morphological manifestation of necrosis (<xref ref-type="bibr" rid="B4">4</xref>). Elevated RIP3 and MLKL were harvested after IRE, and cell morphology was observed with loss of the plasma membrane and release of organelles and chromatin, which is consistent with the morphology of necroptosis (<xref ref-type="bibr" rid="B21">21</xref>). Multiple modes of cell death may exist in the target area after electrical pulses, but they can change over time, and genetic analysis revealed that apoptosis was the predominant mode of cell death after H-FIRE (2000V, 100&#x3bc;s, bipolar pulses, a 2&#x3bc;s positive pulse, 5&#x3bc;s inter-pulse delay, 2;&#x3bc;s negative pulse, and a 5&#x3bc;s inter-pulse delay) was applied to the mouse 4T1 mammary tumor at 2 hours, while necrosis and pyroptosis were predominant by 24 hours (<xref ref-type="bibr" rid="B27">27</xref>). In addition, the mode of cell death can change with parameters, more energy may have greater thermal damage, more necrosis. Brock et&#xa0;al. conducted IRE on utilizing patient-derived xenograft (PDX) models, and found that apoptosis was evident at 500 V/cm but necrosis was more prominent at 2500 V/cm (<xref ref-type="bibr" rid="B23">23</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>Immune response</title>
<sec id="s3_1">
<title>DAMPs and immunity</title>
<p>Common DAMPs include the non-histone chromatin protein high mobility group box 1 (HMGB1), cell surface calcium reticulum protein (CRT), and other endoplasmic reticulum (ER) proteins, and adenosine triphosphate (ATP), which are associated with cell death. CD91, toll-like receptor 4 (TLR4), and The P2X7 receptor (P2RX7) are expressed by dendritic cells (DCs) and promote phagocytosis of dead cells, presentation of tumor antigens, and production of IL-1&#x3b2;, respectively (<xref ref-type="bibr" rid="B35">35</xref>). The release of DAMPs (ATP, calreticulin, nucleic acids and uric acid) increases with increasing pulse amplitude after IRE on cells <italic>in vitro</italic> (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B36">36</xref>&#x2013;<xref ref-type="bibr" rid="B39">39</xref>) and causes massive immune cell aggregation in post-electroporation pancreatic cancer tissue <italic>in vivo</italic> (<xref ref-type="bibr" rid="B36">36</xref>) (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). The release of DAMPs is related to the parameters of the pulses, at IRE (500-1500&#xa0;V, 100 &#x3bc;s, 8-24 pulses) with increasing voltage, the release of DAMP increases (<xref ref-type="bibr" rid="B29">29</xref>), similarly, the number of DAMP releases is related to the number of pulses, after IRE (1000&#xa0;V, 100 &#x3bc;s, 8/40/80 pulses), CRT, ATP, and HMGB1 were released most at 40 pulses and less at 8 and 80 pulses, suggesting that there may be a suitable number of pulses, neither too less nor too more, that would allow the most DAMP release, Go EJ et&#xa0;al. speculated that low pulses (&lt;40) would not induce ICD and high pulses (&gt;40) would lead to rapid cell death, thus limiting DAMP expression (<xref ref-type="bibr" rid="B38">38</xref>). Most of the studies about DAMP are <italic>in vitro</italic>, and the appropriate parameters, as well as the intensity-release dependence, may require further studies.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Effects of pulsed field ablation on tumor microenvironment.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Factors</th>
<th valign="top" align="center">Intervention</th>
<th valign="top" align="center"/>
<th valign="top" colspan="4" align="center">Parameters</th>
<th valign="top" align="center">Mode of action</th>
<th valign="top" align="center">
<italic>In vitro</italic> or <italic>in vivo</italic>
</th>
<th valign="top" align="center">Type of tumor</th>
</tr>
<tr>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
<th valign="top" align="center">V</th>
<th valign="top" align="center">EFS</th>
<th valign="top" align="center">PW</th>
<th valign="top" align="center">PRF</th>
<th valign="top" align="center">N&#x2009;</th>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
<th valign="top" align="center"/>
</tr>
</thead>
<tbody>
<tr>
<th valign="top" colspan="10" align="left">DAMP</th>
</tr>
<tr>
<td valign="top" align="left">1.CRT</td>
<td valign="top" align="left">IRE<break/>&amp;<break/>RE</td>
<td valign="top" align="center">1000<break/>1000<break/>1000</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;<break/>&#x2013;</td>
<td valign="top" align="center">100<break/>100<break/>100</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;<break/>&#x2013;</td>
<td valign="top" align="center">80<break/>40<break/>8</td>
<td valign="top" align="left">24h: Increased by about 6.1 times.<break/>24h: Increased by about 30 times.<break/>24h: Increased by about 6.9 times</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">The Lewis lung carcinoma (LLC, CRL-1642) (<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="5" align="left">2.ATP</td>
<td valign="top" rowspan="2" align="left">IRE<break/>&amp;<break/>RE</td>
<td valign="top" align="center">200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">20</td>
<td valign="top" align="left">Within 30min: No significant difference.</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">KRAS* (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">960<break/>200<break/>960</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;<break/>&#x2013;</td>
<td valign="top" align="center">100<break/>100<break/>100</td>
<td valign="top" align="center">1<break/>1<break/>1</td>
<td valign="top" align="center">20<break/>20<break/>20</td>
<td valign="top" align="left">Within 30min: Increased<break/>Within 30min: Increased slightly<break/>Within 30min: Increased</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">KRAS* (<xref ref-type="bibr" rid="B36">36</xref>)<break/>B16F10 (<xref ref-type="bibr" rid="B36">36</xref>)<break/>B16F10 (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">1000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">80<break/>40<break/>8</td>
<td valign="top" align="left">24h: Increased by about 1.6 times.<break/>24h: Increased by about 8.7 times.<break/>24h: Increased by about 5.4 times.</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">The Lewis lung carcinoma (LLC, CRL-1642) (<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">500<break/>1000</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;</td>
<td valign="top" align="center">100<break/>100</td>
<td valign="top" align="center">1<break/>1</td>
<td valign="top" align="center">20<break/>20</td>
<td valign="top" align="left">Increased</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">KPC (<xref ref-type="bibr" rid="B37">37</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;</td>
<td valign="top" align="center">7000<break/>7000</td>
<td valign="top" align="center">0.2<break/>0.2</td>
<td valign="top" align="center">10<break/>10</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;</td>
<td valign="top" align="left">No significant difference (CT26)<break/>Increased (EL-4)</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">EL-4 lymphoma; CT26 colon carcinoma cells (<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="5" align="left">3. HMGB1</td>
<td valign="top" rowspan="4" align="left">IRE<break/>&amp;<break/>RE</td>
<td valign="top" align="center">200<break/>960</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;</td>
<td valign="top" align="center">100<break/>100</td>
<td valign="top" align="center">1<break/>1</td>
<td valign="top" align="center">20<break/>20</td>
<td valign="top" align="left">Within 30min: No significant difference at 200V, increased at 960V.</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">KRAS* (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">200<break/>960</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;</td>
<td valign="top" align="center">100<break/>100</td>
<td valign="top" align="center">1<break/>1</td>
<td valign="top" align="center">20<break/>20</td>
<td valign="top" align="left">Within 30min: No significant difference at 200V, increased at 960V.</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">B16F10 (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">500&#x2013;1500</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">8<break/>16<break/>24</td>
<td valign="top" align="left">24h: Increased in a&#xa0;strength-dependent manner.</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">Panc-1, Bxpc-3, Pan02 (<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">1000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">8<break/>40<break/>80</td>
<td valign="top" align="left">24h: Increased by about 7.3 times.<break/>24h: Increased by about 12.3 times.<break/>24h: No increase.</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">The Lewis lung carcinoma (<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;</td>
<td valign="top" align="center">7000<break/>7000</td>
<td valign="top" align="center">0.2<break/>0.2</td>
<td valign="top" align="center">10<break/>10</td>
<td valign="top" align="center">&#x2013;<break/>&#x2013;</td>
<td valign="top" align="left">Increased<break/>Increased</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">EL-4 lymphoma; CT26 colon carcinoma cells (<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">4.HSP70</td>
<td valign="top" align="left">IRE<break/>&amp;<break/>RE</td>
<td valign="top" align="center">500&#x2013;1500</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">24<break/>16<break/>8</td>
<td valign="top" align="left">24h: Increased in a&#xa0;strength-dependent manner</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">Panc-1, Bxpc-3, Pan02 (<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">5.Calreticulin</td>
<td valign="top" align="left">IRE<break/>&amp;<break/>RE</td>
<td valign="top" align="center">500&#x2013;1500</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">24<break/>16<break/>8</td>
<td valign="top" align="left">24h: Increased in a&#xa0;strength-dependent manner</td>
<td valign="top" align="left">
<italic>In vitro</italic>
</td>
<td valign="top" align="left">Panc-1, Bxpc-3, Pan02 (<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="10" align="left">Phagocytes</td>
</tr>
<tr>
<td valign="top" align="left">1.Macrophages</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">80</td>
<td valign="top" align="left">Day 7: M1 polarized and Increased in a&#xa0;strength-dependent manner<break/>Day 7: M2 decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B29">29</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">2.DC</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 9: No significant difference.</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left">3.NK</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: decreased<break/>Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B37">37</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="10" align="left">
<bold>Cytokines and complements</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">IL-1a</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">3000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">2 h: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left">IL-1b</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">3000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">2 h: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">30000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">400</td>
<td valign="top" align="left">Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="3" align="left">IL-2</td>
<td valign="top" rowspan="2" align="left">IRE</td>
<td valign="top" align="center">3000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">2 h: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 7: increased (more than Day 3 and preOP)</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-5</td>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="3" align="left">IL-6</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: increased<break/>Day 7: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">30000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">400</td>
<td valign="top" align="left">Day 3: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="3" align="left">IL-10</td>
<td valign="top" rowspan="2" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: increased<break/>Day 7: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">3000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">2 h: increased<break/>Day 2: increased dramatically</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-12</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">3000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">2 h: increased<break/>Day 2: increased dramatically</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-17A</td>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-17F</td>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-21</td>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IL-22</td>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="3" align="left">IFN-&#x3b3;</td>
<td valign="top" rowspan="2" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">No significant difference</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">3000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">2 h: increased<break/>Day 2: increased dramatically</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="3" align="left">TNF-&#x3b1;</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">3000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">2 h: increased<break/>Day 2: increased dramatically</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left">nsPEF</td>
<td valign="top" align="center">30000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">400</td>
<td valign="top" align="left">Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">GM-CSF</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">3000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">2 h: increased<break/>Day 2: increased dramatically</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">C3</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: decreased<break/>Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">C4</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: decreased<break/>Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="10" align="left">
<bold>Immune-suppressive cells</bold>
</td>
</tr>
<tr>
<td valign="top" rowspan="6" align="left">1.Treg</td>
<td valign="top" rowspan="3" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: increased<break/>Day 7: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">1500</td>
<td valign="top" align="center">90</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Week 2: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B46">46</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 9: No significant difference</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">30000</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">400</td>
<td valign="top" align="left">Day 3: slightly increased<break/>Day 7: significantly decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">30000</td>
<td valign="top" align="center">0.1</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">200</td>
<td valign="top" align="left">Day 4: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">Malignant melanoma (<xref ref-type="bibr" rid="B67">67</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">H-FIRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">2500</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 2: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">4T1 mammary tumor (<xref ref-type="bibr" rid="B27">27</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">2.TAM</td>
<td valign="top" align="left">H-FIRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">2500</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 2: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">4T1 mammary tumor (<xref ref-type="bibr" rid="B27">27</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">3.MDSC</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">1500</td>
<td valign="top" align="center">90</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 14: eMDSC decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B46">46</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" rowspan="2" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">30000</td>
<td valign="top" align="center">0.3</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">400</td>
<td valign="top" align="left">Day 3&amp;7: nMDSC &amp; mMDSC decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">30000</td>
<td valign="top" align="center">0.1</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">200</td>
<td valign="top" align="left">Day 4: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">Malignant melanoma (<xref ref-type="bibr" rid="B67">67</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left">H-FIRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">2500</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 2: pMDSC decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">4T1 mammary tumor (<xref ref-type="bibr" rid="B27">27</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">4.TAN</td>
<td valign="top" align="left">H-FIRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">2500</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 2: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">4T1 mammary tumor (<xref ref-type="bibr" rid="B27">27</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="10" align="left">Adaptive immunity</td>
</tr>
<tr>
<td valign="top" rowspan="4" align="left">CD 4+ T cell</td>
<td valign="top" rowspan="3" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Week 2: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 9: No significant difference</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: decreased<break/>Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">300</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="4" align="left">CD 8+ T cell</td>
<td valign="top" rowspan="3" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 9: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: decreased<break/>Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="center">1000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">90</td>
<td valign="top" align="left">increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B70">70</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">300</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">B cell</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 9: No significant difference</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">300</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="left">Day 8: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IgA</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3&amp;7: No significant difference</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IgG</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3: decreased<break/>Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">IgM</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="left">Day 3&amp;7: No significant difference</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B50">50</xref>)</td>
</tr>
<tr>
<td valign="top" colspan="10" align="left">
<bold>Vasculature, extracellular matrix, and chemical environment</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">VEGF</td>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">0.1</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="left">1h: decrease</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B21">21</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">CD31</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">80</td>
<td valign="top" align="left">Day 7: increased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B46">46</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 4: transient increase<break/>Day 6: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">CD34</td>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">20000</td>
<td valign="top" align="center">0.1</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="left">1h: decrease</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">Hep-3B HCC (<xref ref-type="bibr" rid="B21">21</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">FITC-conjugated dextran</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 4: increased<break/>Day 6: decrease, but still higher than that of untreated tumors</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">FAP&#x3b1;</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 4: decreased<break/>Day 6: rebounded back</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">HABP1</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 6: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">80</td>
<td valign="top" align="left">Day 3: decreased<break/>Day 7: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">LOX</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">80</td>
<td valign="top" align="left">Day 3: decreased<break/>Day 7: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B46">46</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 6: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">&#x3b1;- SMA</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 6: No significant difference</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center">1000</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">80</td>
<td valign="top" align="left">Day 3&amp;7: No significant difference</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">MMP</td>
<td valign="top" align="left">nsPEF</td>
<td valign="top" align="center"/>
<td valign="top" align="center">20000&#x2013;60000</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="left">1 h: decrease</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">HCC (<xref ref-type="bibr" rid="B21">21</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">CA-IX</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 6: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">HIF-1&#x3b1;</td>
<td valign="top" align="left">IRE</td>
<td valign="top" align="center">1200</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">100</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">99</td>
<td valign="top" align="left">Day 6: decreased</td>
<td valign="top" align="left">
<italic>In vivo</italic>
</td>
<td valign="top" align="left">PC (<xref ref-type="bibr" rid="B36">36</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>V, Voltage (V); EFS, electric field intensity (V/cm); PW, Pulse width&#x2009;(&#xb5;s); PRF, Pulse repetition frequency&#x2009;(Hz); N, Number of pulses; min, minutes; h, hour; HCC, hepatic cancer; PC, pancreatic cancer; RE, reversible electroporation; IRE, irreversible elecrtroporation; nsPEF, nanosecond pulsed electric fields; H-FIRE, High-frequency irreversible electroporation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>(i) CRT is the most abundant in the endoplasmic reticulum. After activation of ICD-related signaling pathways, it transfers from the endoplasmic reticulum to the cell membrane surface and can interact with transmembrane receptors including CD49, CD69, CD91 (also known as the low density lipoprotein (LDL) receptor-related protein-1 (LRP1)), and integrins. The most important is the CD91 molecule. CRT releases effective phagocytic signals to CD91-positive cells (mainly macrophages and DCs) and causes the production of pro-inflammatory cytokines (including IL-6 and TNF-&#x3b1;) (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B40">40</xref>). (ii)In addition to participating in purinergic neurotransmission, ATP released from damaged cells can bind to the P2Y2 receptor of macrophages, promoting the infiltration of macrophages in tumor sites, and can also bind to the P2RX7 of DC cells, leading to DC maturation and release of IL-1&#x3b2;. (iii) HMGB1 can bind to protein toll-like receptor 4 (TLR-4) and receptor for advanced glycation end products (RAGE) to activate monocytes/macrophages. HMGB1 can also upregulate costimulatory molecules and major histocompatibility complex (MHC) class II to transfer immature DC to mature DC (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). HMGB1 stimulates neutrophils and monocytes, enabling these cells to adhere to activated vascular endothelium and migrate to inflamed tissues (<xref ref-type="bibr" rid="B43">43</xref>).</p>
<p>Electrical pulse stimulation triggers the release of DAMPs, which acts as a &#x201c;find me&#x201d; signal, enhances tumor immunogenicity and subsequently induces antigen-presenting cells (APC) activation. These signals enhance the ability of APC to phagocytose, process, and present tumor-derived antigens to T cells, thereby facilitating the induction of tumor-specific adaptive immunity. So, the level of these DAMPs and cells increases after pulsed electric field (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B36">36</xref>&#x2013;<xref ref-type="bibr" rid="B39">39</xref>).</p>
</sec>
<sec id="s3_2">
<title>Innate immune</title>
<sec id="s3_2_1">
<title>Phagocytes</title>
<p>There are many phagocytic cells in the body, and the first one worth mentioning is macrophages. Macrophages have multiple functions: phagocytosis of dead cells and debris; acting as APC to process antigens and participate in adaptive immunity through MHC molecules; production and secretion of cytokines, including IL-1, IL-6, TNF-&#x3b1;, etc (<xref ref-type="bibr" rid="B44">44</xref>).</p>
<p>Polarized macrophages mainly exist in two distinct subsets: M1 and M2. The secreted cytokines are the key feature to distinguish the two: M1 type can secrete IL-6, IL-12 and tumor necrosis factor (TNF), M2 type can secrete IL-10, IL-1 receptor antagonist (IL-1ra), and the type II IL-1 decoy receptor. Type M1 is an effective inflammatory effector cell that can produce a large number of cytokines and kill tumor cells through the production of ROS. Type M2 is more inclined to promote angiogenesis and promote fibrosis to remodel and repair tissues (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>). Tumor-associated macrophages (TAM) have a phenotype and function similar to M2 macrophages, which reduce the killing of tumor cells by cytotoxic T cells and NK cells (<xref ref-type="bibr" rid="B45">45</xref>). Tumor cells secrete chemokine (C-C motif) ligand 2 (CCL-2) (lung tumors, breast cancer, cervical cancer, ovarian cancer, etc.) to cause the accumulation of macrophages. Low levels of CCL-2 promote tumor growth, and high levels of CCL-2 cause a large number of macrophages to accumulate and tumor destruction (<xref ref-type="bibr" rid="B45">45</xref>). After pancreatic ductal cell adenocarcinoma (PDAC) undergoes electroporation, the expression of CD16/32 in macrophages (a hallmark of M1 macrophages) increases and changes from a rod shape to a round shape, indicating that the formation of irreversible electroporation can induce M1 macrophages polarization of cells. In addition, positive-feedback release or expression of HMGB1 and RAGE in macrophages <italic>via</italic> the MAPK-ERK pathway promoted M1 macrophage polarization (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B38">38</xref>), and M1/M2 ratio tends to increase in a&#xa0;strength-dependent manner (<xref ref-type="bibr" rid="B29">29</xref>). In addition to the MAPK - ERK pathway, a stimulator of interferon genes (STING) signaling is involved in the activation and repolarization of macrophages, one study found that this macrophage repolarization was most pronounced when tumors were treated with a combination of IRE and STING agonist (<xref ref-type="bibr" rid="B38">38</xref>).</p>
<p>After the electric pulse acts on the tissue, in addition to macrophages, the ablation zone also found the accumulation and activation of neutrophils, DC cells, and NK cells (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). Like macrophages, these phagocytes can kill perforated cells (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>Immature DC cells highly express TLRs, opsonizing receptors, etc. After receiving the DAMPs signal released by the perforated cells, the low-expressed MHC class II molecules and costimulatory molecules are activated to become mature DC cells, which effectively present antigens in adaptive immunity (<xref ref-type="bibr" rid="B48">48</xref>). After electric pulse treatment of mouse KRAS* cells <italic>in vitro</italic>, the CD40, MHC-II, chemokine receptor (CCR) 7, and CD86 surface markers of DC cells increased relatively, which suggested the activation of DC cells (<xref ref-type="bibr" rid="B36">36</xref>). Combining IRE and DC vaccines for mouse pancreatic cancer, it can be found that IRE can overcome the immunosuppressive environment of pancreatic cancer, thereby enhancing the effect of DC vaccination (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>NK cells can be defined into two subsets according to the levels of CD56 and CD 16: CD56<sup>hi</sup> CD16<sup>&#xb1;</sup> and CD56<sup>lo</sup> CD16<sup>hi</sup>, the former promoting the inflammatory response by releasing cytokines and the latter killing cells by perforin and granzyme (<xref ref-type="bibr" rid="B49">49</xref>). IRE can increase the concentration of mouse NK1.1 cells in the blood and tumor accumulation in animal experiments (<xref ref-type="bibr" rid="B37">37</xref>), and it can also cause an increase in peripheral blood NK cells in humans (<xref ref-type="bibr" rid="B50">50</xref>). NK cell therapy can also increase the killing effect on tumor cells. The combination of IRE ablation and NK cells can have a synergistic therapeutic effect on stage IV hepatocellular carcinoma. The combined treatment group&#x2019;s IL-2, tumor necrosis factor (TNF), and interferon (IFN) levels are higher in both groups than in the single treatment group. Synergistic treatment of liver cancer with IRE and NK also increases the levels of lymphocytes and Th1-type cytokine decreases the expression of alpha-fetoprotein and increases the survival time of patients (<xref ref-type="bibr" rid="B49">49</xref>). So, increasing NK cells will inhibit tumor growth, and electrical pulses can have a synergistic effect with NK cell therapy.</p>
</sec>
<sec id="s3_2_2">
<title>Cytokines</title>
<p>Chen X found IL-1a, IL-1ra, IL-1b, IL-2, IL-6, IL-8, and IL-18 levels are significantly higher 2 hours after IRE ablation. IL-4, IL-10, IL-12, TNF-a, IFN-r, granulocyte-macrophage colony-stimulating factor (GM-CSF) increased dramatically 2 days after ablation (<xref ref-type="bibr" rid="B51">51</xref>). Most of these cytokines can activate cytotoxic immunity, including IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, and IL-15. IL-16 and IL-17 also facilitate cellular immunity (<xref ref-type="bibr" rid="B52">52</xref>). And Chen X&#x2019;s result indicated that changes the abnormal drifted Th2 in HCC back to Th1 status (<xref ref-type="bibr" rid="B51">51</xref>). Zhao et&#xa0;al. found that after seven days the TNF-&#x3b1; and IL-1&#x3b2; levels in blood were increased, while IL-6 levels were decreased (<xref ref-type="bibr" rid="B53">53</xref>). IFN-&#x3b3; stimulates antigen presentation and cytokine production by monocyte, and also stimulates monocyte adhesion, phagocytosis, and other effector functions. One of the most important biological activities of IL-1 is its ability to activate T lymphocytes by enhancing IL-2 production and IL-2 receptor expression. IL-6 is mainly produced by monocytes and mediates T cell activation, growth, and differentiation (<xref ref-type="bibr" rid="B52">52</xref>). IL-10 is a compound with both immunosuppressive and anti-angiogenic functions and is a direct inhibitor of Th1 function (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). Yimingjiang et&#xa0;al. found significantly higher IL-10 in tumor-bearing mice after nanosecond pulses than in controls (<xref ref-type="bibr" rid="B56">56</xref>), while He et&#xa0;al. found that after IRE, IL-10 levels in pancreatic cancer increased on day 3 and decreased on day 7 (<xref ref-type="bibr" rid="B46">46</xref>). The immunosuppressive effect of IL-10, the function of recruitment to Treg makes IL-10 seem to promote tumor growth, while the changes in IL-10 levels after electrical pulses vary from experiment to experiment and need to be further verified (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B56">56</xref>).</p>
<p>Thus, electrical pulses can activate phagocytosis, adhesion phagocytosis, activation of T lymphocytes, and induction of cytotoxic T lymphocyte (CTL) direct killer cells for immune response to post-perforation cells by triggering the secretion of pro-inflammatory cytokines <italic>in vivo</italic>.</p>
</sec>
</sec>
<sec id="s3_3">
<title>Immune-suppressive cells</title>
<p>A large number of immunosuppressive cells are present in tumors, including T regulatory cells (Tregs), tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and myeloid-derived suppressor cells (MDSCs), and the upregulation of these cell types in tumors depends on the reciprocal signaling between these cells and tumor cells.</p>
<p>The production of Treg (usually CD4+CD25<sup>+</sup>Foxp3<sup>+</sup> T cells) depends mainly on transforming growth factor-&#x3b2; (TGF-&#x3b2;) and IL-2, which negatively regulate immunity and can produce TGF-&#x3b2; and IL-10 to suppress immune responses (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>). And Tregs&#x2019; infiltration is negatively correlated with median survival OS in many patients with solid tumors (<xref ref-type="bibr" rid="B59">59</xref>). Tregs can effectively suppress effector T lymphocytes and can inhibit the function of B, NK, dendritic cells, and macrophages through different mechanisms (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B60">60</xref>).</p>
<p>TAM has an M2 macrophage-like phenotype and promotes tumor progression through several mechanisms: secretion of VEGF, which promotes tumor angiogenesis; promotion of tumor invasion mainly through the release of metalloproteinases, matrix remodeling enzymes, and chemotactic growth factors from the environment; and suppression of innate immune responses (<xref ref-type="bibr" rid="B61">61</xref>).</p>
<p>There are mainly two types of MDSC: polymorphonuclear MDSC (P-MDSC) which resemble neutrophils morphologically and phenotypically, and monocyte MDSC (M-MDSC) which resemble monocytes. MDSC has potent immunosuppressive activity through multiple pathways: promoting Tregs&#x2019; production and promoting fibroblast differentiation into cancer-associated fibroblasts (CAF) depleting L-arginine eliminates key trophic factors required for T cell proliferation, nitrates chemokines and blocks CD8+ T cells from entering the tumor, and produces immunosuppressive cytokines such as IL-10 and TGF-&#x3b2; (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>).</p>
<p>Unlike normal myofibroblasts, CAF does not undergo apoptosis and can release various cytokines and MMPs to hydrolyze extracellular matrix, stimulate angiogenesis and promote tumor growth and invasion (<xref ref-type="bibr" rid="B63">63</xref>). (As described in 4. Vasculature, extracellular matrix, and chemical environment).</p>
<p>Reduction of systemic Tregs in locally advanced pancreatic cancer (LAPC) patients 2 weeks after IRE was found in clinical trials (<xref ref-type="bibr" rid="B64">64</xref>). However, a transient increase in Tregs on day three followed by a decrease on day seven was found in the clinical trial by He C (<xref ref-type="bibr" rid="B46">46</xref>). Similar results were also found in Harshul et&#xa0;al.&#x2019;s study, where LAPC patients could have a procedure-mediated Treg attenuation between the third and fifth day after IRE (<xref ref-type="bibr" rid="B65">65</xref>). A reduction in Li<sup>-</sup> CD<sup>33+</sup> HLA<sup>-</sup>DR<sup>-</sup> early myeloid-derived suppressor cells (eMDSC) was observed 2 weeks after IRE treatment (<xref ref-type="bibr" rid="B64">64</xref>). IRE combined with OX40 agonist induced a significant reduction in MDSC in primary and distant tumors (<xref ref-type="bibr" rid="B66">66</xref>). H-FIRE resulted in a reduction of MDSCs and TAMs in the tumor microenvironment of mammary carcinoma in mice 2 days after procedure (<xref ref-type="bibr" rid="B27">27</xref>). NsPEF treated with C57 malignant melanoma reduced Treg cells from 4.3% to 2.4% and MDSC by 39.0% to 19.7%, which was observed 4 days later (<xref ref-type="bibr" rid="B67">67</xref>). NsPEF can act on mice with pancreatic cancer after 3 days postoperative, 7 days postoperative decreased the percentage of nMDSCs and mMDSCs in the spleen, although Tregs slightly increased at 3 days postoperatively, but significantly decreased at 7 days postoperative (<xref ref-type="bibr" rid="B53">53</xref>), indicates that the immunosuppressed state can be reversed in this period of time, which would facilitate the combination with immunotherapy.</p>
<p>Therefore, electrical pulses can inhibit the proliferation of tumor-associated immune cells in the tumor microenvironment and promote anti-tumor responses to create an immune environment conducive to tumor suppression. However, the reversion of immunosuppression after IRE or nsPEF is time-dependent and this may start after day 3, but a longer and more subtle follow-up is needed to determine the time window for combination with immunotherapy.</p>
</sec>
<sec id="s3_4">
<title>Adaptive immunity</title>
<p>Adaptive immunity is achieved through regulated interactions between APC and T and B cells. Circulating antigens or APC-treated antigens are presented to T and B cells, eliciting cellular and humoral immunity, respectively. The largest T cell population in the body is the CD4+&#x3b1;&#x3b2; T cell receptor (TCR) population. Most of these cells have a helper function and are called helper T (Th) cells, which produce many cytokines. CTL is a type of CD8+ T cells that kill target host cells through a contact-dependent mechanism: increased expression of FasL on CTL binds to Fas receptors in target tissues, participates in apoptosis, and acts on target cells by releasing substances such as perforin and granzyme. Adaptive humoral immunity is mediated by antibodies produced by plasma cells (<xref ref-type="bibr" rid="B55">55</xref>).</p>
<p>Several studies have found that electrical pulses acting on cells induce increased circulation and ablation foci of CD8+ T cells (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B68">68</xref>&#x2013;<xref ref-type="bibr" rid="B70">70</xref>), and some experiments have found elevated CD4+ levels (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>), however, some studies has also shown no significant increase in CD4+ levels (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B23">23</xref>) (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). Zhao et&#xa0;al. found an increased CD8+ T cells and CD4+ T after nanosecond pulses acting on pancreatic cancer in mice, and a significantly higher CD8/CD3 ratio in tumors compared to controls (<xref ref-type="bibr" rid="B53">53</xref>). He et&#xa0;al. found an increase of effector CD8+ T cells, effector CD4+ T cells, and memory T cells at 7 days after IRE, despite decrease at day 3, so it can effectively induce the activation of T cells over a period of time, and the experiment also found that IRE can inhibit the growth of potential tumors through the distant effect (<xref ref-type="bibr" rid="B50">50</xref>). However, Dai et&#xa0;al. implied that IRE treatment significantly inhibited HCC growth by more CD8+ T and dendritic cells, but not CD4+ T or B cells infiltrating into the peri-ablative region. CD8+ depleted T cells induced local tumor regeneration and distant metastasis after IRE (<xref ref-type="bibr" rid="B10">10</xref>). Most of the IRE or nsPEF studies have activated the proliferation of CD8+T, but the proliferation of CD4+T is not obvious in some studies, revealing that CD8+ T-mediated cellular immunity plays a great role in electric pulses induced immunity. Effective T cell initiation requires several events, including: release of endogenous antigens from cancer cells, release of &#x201c;danger signals&#x201d; from damaged cells, processing of cancer antigens, antigens presented to naive T cells by APC, activation and proliferation of cancer-specific cytotoxic T cells (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B71">71</xref>). The current results suggest that pulsed electric field can promote cellular immunity through these sessions: 1) induce immunogenic death, resulting in the massive release of DAMP (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>); 2) Proliferation and activation of antigen presenting cells (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B38">38</xref>); 3) Activation, proliferation and function of cancer-specific cytotoxic T cells (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B70">70</xref>). In addition, Shao et&#xa0;al. compared IRE, thermal therapy (Heat), cryosurgery (Cryo) <italic>in vitro</italic>, and found that IRE can cause more protein release than other ablation. Although the released protein has 40% denatureation, T cell proliferation is still 2-3 times higher than Cryo (<xref ref-type="bibr" rid="B69">69</xref>). IRE induces OX40 expression in CD8+ T cells <italic>in vivo</italic>, and OX40 acts as a co-stimulatory molecule to increase T cell expansion and cytokine secretion (<xref ref-type="bibr" rid="B66">66</xref>). The combination of IRE and TLR 3/9 agonists and PD-1 blockade can effectively reverse the depletion of intratumoral CD8+T and enhance local immunity against tumors (<xref ref-type="bibr" rid="B72">72</xref>). Brandon et&#xa0;al. made a deeper exploration by combining anti-T-lymphocyte-associated protein-4 (anti-CTLA-4) therapy prior with IRE on prostate cancer to promote neoantigen-specific T-cell responses, resulting in increased numbers of splenic systemic SPAS-1+ T cells concentrated in tumors and distant sites. Circulating memory CD8+ T cells, in addition to central memory (T<sub>CM</sub>) and effector memory (T<sub>EM</sub>), have tissue-resident memory (T<sub>RM</sub>). Endogenous SPAS-1 neoantigen-specific CD8+ T cells were increased in number and enriched in tumors following TRAMP-C2 tumor cell were attack and generated CD8+ T<sub>RM</sub> cells in different tissues (<xref ref-type="bibr" rid="B68">68</xref>). In addition, Shi et&#xa0;al. treated hepatocellular carcinoma (HCC) with IRE in combination with an anti-PD-L1 monoclonal antibody and found enhanced off-target necrosis and inflammatory infiltration, with IRE significantly increasing the inflammatory infiltration index and increasing CD8+ T infiltration not only in target tissues but also in non-target tissues (untreated tumors) (<xref ref-type="bibr" rid="B70">70</xref>). Immunotherapy Combined IRE induced more CD8+ T proliferation and enrichment in tumors as well as other sites than immunotherapy alone, probably because: 1) IRE increased its immunogenicity: IRE caused immunogenic death of tumor tissues, massive release of DAMPs, causing activation of APCs and presentation to T cells, leading to tumor specific T-cell population expansion and enhanced systemic antitumor effects; 2) Reversal of the immune tolerant tumor microenvironment, with M1 macrophages polarizing CD4+ Th1 cell differentiation to enhance CD8+ T cell survival and tumor infiltration; 3) IRE-induced regulation of the tumor stroma, extracellular matrix, and/or vascular system may be another reason (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B73">73</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>Vasculature, extracellular matrix, and chemical environment</title>
<sec id="s4_1">
<title>Vasculature</title>
<p>Several studies have demonstrated the protective effect of ablation foci on large vessels (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B74">74</xref>). For example, researchers followed 158 vessels with a mean distance of 2.3 &#xb1; 2.5&#xa0;mm from the treatment area and found only 7 (4.4%) with abnormal vascular changes, including stenosis and thrombosis (<xref ref-type="bibr" rid="B9">9</xref>). However, the effect of IRE on microvessels is uncertain, and in some studies, microvessels remain histopathologically preserved in the area after ablation and the structure is still present (<xref ref-type="bibr" rid="B75">75</xref>), but can show microvascular distortion, occlusion, and thrombosis when observed under electron microscopy (<xref ref-type="bibr" rid="B32">32</xref>), and after disruption of vascular continuity there can be hemorrhagic necrosis with infiltration of surrounding neutrophils (<xref ref-type="bibr" rid="B76">76</xref>), and endothelial cells are damaged significantly. Thereafter, the disrupted vessel can be recognized by new endothelial cells derived from neighboring cells and/or circulating endothelial progenitor cells (<xref ref-type="bibr" rid="B32">32</xref>). Non-thermal irreversible electroporation can cause a decellularizing effect of the vessel at 3 days, the vessel skeleton survives while cells are shed, however, at 7 days this skeleton has endothelial ingrowth (<xref ref-type="bibr" rid="B74">74</xref>).</p>
<p>The changes of the microvasculature after IRE are: immediate congestion (<xref ref-type="bibr" rid="B75">75</xref>); necrosis of endothelial cells, hemorrhage, and peripheral inflammatory response (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B76">76</xref>); and there can be regeneration of new vessels (<xref ref-type="bibr" rid="B32">32</xref>). It is worth mentioning that in Lv et&#xa0;al.&#x2019;s theoretical study of the effect of perforation on tumor vasculature and normal vasculature, by establishing a multilayer dielectric model, explored that rich vascular smooth muscle cells (VSMCs) might have a protective effect on normal vasculature, thus demonstrated that electroporation may have a stronger destructive effect on tumor vasculature (<xref ref-type="bibr" rid="B77">77</xref>).</p>
<p>At the level of regulation of angiogenesis, tumor growth requires nutritional support from blood vessels, and angiogenesis is influenced by the expression of pro-angiogenic factors and anti-angiogenic factors; the VEGF family, composed of six growth factors (VEGFA-F), is essential for angiogenesis (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B79">79</xref>), and angiopoietin 1-2 (Ang1-2) is independent of VEGF, while Ang-2 is mainly present in vascular expressed in remodeled tissues and in the hypoxic tumor microenvironment (<xref ref-type="bibr" rid="B80">80</xref>). VEGF can also exert inhibitory effects on DC cells and effector T cells in driving neoangiogenesis, as well as increase TAM infiltration and the expansion of Tregs and MDSCs (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B81">81</xref>&#x2013;<xref ref-type="bibr" rid="B84">84</xref>). However, due to the overexpression of pro-angiogenic factors and less in tumors, tumor vessels exhibit functional abnormalities with abnormal leakage, rapid growth, high tortuosity, and little perivascular pericytes and smooth muscle cells coverage (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B79">79</xref>). A decrease in VEGF and CD34 proteins can be detected 1 hour after nanosecond pulse treatment of pancreatic cancer (<xref ref-type="bibr" rid="B21">21</xref>). He et&#xa0;al. also found increased expression of CD31 in tumor after IRE (<xref ref-type="bibr" rid="B53">53</xref>). In addition, nsPEFs and everolimus (The mammalian target of rapamycin (mTOR) inhibitor) synergistically inhibited angiogenesis by decreasing the expression of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), and CD34 (<xref ref-type="bibr" rid="B85">85</xref>). In addition to inhibiting the expression of pathological proangiogenic factors, a study by Zhao et&#xa0;al. found a transient increase in CD31 calculated tumor microvascular density microvessel density (MVD) followed by a decrease four days after IRE treatment of pancreatic cancer and an increase in microvascular permeability determined by fluorescein isothiocynate (FITC)-bound dextran (<xref ref-type="bibr" rid="B73">73</xref>). Therefore, pulsed electric field can inhibit the growth of tumor pathological blood vessels and blood supply around the tumor, and also preserve the permeability of functional blood vessels to a certain extent, which is conducive to the infiltration of immune cells and factors.</p>
</sec>
<sec id="s4_2">
<title>Extracellular matrix</title>
<p>In the tumor microenvironment, not only tumor cells proliferate rapidly, but also stromal deposition and remodeling as well as cancer cells and stromal cells increase, and CAFs form the main support structure of tumor tissues (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). CAFs also promote cancer development by secreting growth-promoting factors such as TGF-&#x3b2;, stromal degrading enzymes and angiogenic factors such as MMP or VEGF, &#x3b1; smooth muscle actin (&#x3b1;-SMA) is a reliable biomarker for CAFs, and fibroblast activating protein &#x3b1; (FAP-&#x3b1;, seprase) is a surface glycoprotein that is selectively expressed on solid tumor fibroblasts. MMP hydrolyzes the extracellular matrix and its expression correlates with the aggressive phenotype of tumor cells and tumor progression (<xref ref-type="bibr" rid="B86">86</xref>).</p>
<p>Extracellular matrix and collagen structures can exist intact after IRE action because IRE acts on phospholipid bilayers (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B74">74</xref>).</p>
<p>MMPs family proteins (MMP1, MMP2, MMP9, MMP11, MMP12, MMP14, and MMP21) are expressed at different levels of nsPEF intensity (<xref ref-type="bibr" rid="B21">21</xref>). In a study by Zhao et&#xa0;al. collagen matrix or &#x3b1;SMA+ CAFs were not affected by IRE, and FAP-&#x3b1;, hyaluronic acid (indicated by HABP1 expression levels) and lysyl oxidase (LOX, a marker of extracellular matrix stiffness) were decreased to varying degrees (<xref ref-type="bibr" rid="B36">36</xref>). Vasculature and collagen were still present in IRE-treated lung tissue 2 days after treatment and 28 days after a significant increase, indicating remodeling and regeneration of the mesenchyme, but decorin and heparan sulfate decreased after ablation (<xref ref-type="bibr" rid="B87">87</xref>).</p>
<p>Therefore, when electric pulses cause irreversible electroporation of cells, the presence of stromal and collagen structures can be observed histopathologically, but they can also microscopically modulate the cellular matrix and reduce the levels of CAFs and MMPs (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). With the preservation of functional vessels and increased vascular permeability, softened extracellular matrix is beneficial to infiltration of inflammation and distant effects (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B67">67</xref>).</p>
</sec>
<sec id="s4_3">
<title>Improving hypoxia</title>
<p>Tumor vessels show characteristics of tortuous, twisted, and easily occluded, and the tumor presents a relatively hypoxic state due to the rapid proliferation of tumor cells and the increase of extracellular matrix leading to the increase of tumor tissue pressure. Hypoxia leads to the accumulation of hypoxia-inducible factor 1-&#x3b1; (HIF-1&#x3b1;), which promotes further tumor angiogenesis and suppresses T-cell function (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B88">88</xref>). Moreover, hypoxia increases anaerobic enzymes and lactate accumulation further reduces T and NK cell activation (<xref ref-type="bibr" rid="B89">89</xref>). Reversal of intratumoral hypoxia effectively increases the infiltration of immune cells. The downregulation of HIF-1&#x3b1; and carbonic anhydrase 9 (CA-IX) and increased vascular permeability after IRE suggest that IRE may also increase the number and action of local T cells, NK cells by alleviating tumor hypoxia (<xref ref-type="bibr" rid="B36">36</xref>).</p>
</sec>
</sec>
<sec id="s5" sec-type="discussion">
<title>Discussion</title>
<p>Compared with other local thermal techniques, pulsed electric field has several advantages in the regulation of the microenvironment: 1) It can protect the structure of large and medium vessels, and the elastic fibers and smooth muscle fibers in vessels can maintain the basic normal structure of vessels, with some damaged endothelial cells can be replaced (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B74">74</xref>). 2) The protection of functional blood vessels makes sure the cell&#x2019;s &#x201c;eat me&#x201d; signals be found and recognized by APC (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B43">43</xref>). 3) APC presents antigens to activate immunity, and the retained blood vessels are more conducive to the infiltration of immune cells, which may reduce the occurrence of residual cancer (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B46">46</xref>). 4) Triggering a shift from the innate immunosuppressive microenvironment to the immune-promoted antitumor microenvironment (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B70">70</xref>). Combining pulsed electric field therapy with immunotherapy is beneficial to mobilize the body&#x2019;s immunity to kill tumors (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B68">68</xref>). 5) It promotes systemic immunization and has the effect of distant effect, inhibiting tumors that may metastasize elsewhere (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B70">70</xref>).</p>
<p>Although many studies of the effect of electric pulses on tumor microenvironment have been reported, there are still some questions that need to be addressed and more in-depth studies can be done in the future in the following areas.</p>
<list list-type="order">
<list-item>
<p>The differences in the effects of IRE, nsPEF, and H-FIRE on cell and microenvironment need to be further studied. They have different parametric characteristics, the most prominent of which is the difference in pulse duration. They are capable of disrupting the structure of the cell membrane. However, nsPEF is characterized by high compression power, ultrashort pulse duration, fast rise time, and high electric field. When the pulse duration is shorter than the charging time of the cell membrane (mostly 100 ns), the charge cannot accumulate on the surface of the cell membrane and the applied electric field is mainly received by the membranes of intracellular organelles such as the nucleus, endoplasmic reticulum and mitochondria. When a 300 ns pulse (or longer) is applied, the pulse is long enough to allow the electric field to interact only with the plasma membrane and not the intracellular organelles (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B91">91</xref>). The change of subcellular membrane potential may affect a series of signaling pathways. IRE and nsPEF are different in causing cell damage, which needs further study.</p>
</list-item>
<list-item>
<p>Even though it is the same modality, different parameters can bring about different changes. In IRE, the most studied is the voltage/field strength. Compared to a field strength of 500 V/cm, IRE using 2500 V/cm seems to be more capable of causing cellular damage, whether this is a thermal or non-thermal effect and by what exact mechanism of damage (including membrane damage, ATP depletion, mitochondrial damage, increase in ROS, DNA and protein damage) needs to be further investigated (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B36">36</xref>). And changes in electric field strength bring about proportional changes in the mode of cell death, with the promotion of apoptosis evident at 500 V/cm but increased necrosis at 2500 V/cm (<xref ref-type="bibr" rid="B23">23</xref>), in between which there should be a suitable range of electric field strength that would keep the ablation zone within the desired range and cause more immunogenic death, but the appropriate field strength may vary with the conductivity of the ablated tissue changes.</p>
</list-item>
<list-item>
<p>The complex cascade of responses induced by IRE, nsPEF, and H-FIRE remains to be investigated. The effect of pulsed electric fields on Wnt/&#x3b2;-Catenin, KRAS, EGFR, and downstream NF-&#x3ba;B signaling may be critical in determining therapeutic strategies, as these signals are often dysregulated in tumorigenic development (<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>). More studies should address the complex signaling cascade response activated after pulsed electric fields.</p>
</list-item>
<list-item>
<p>The structure of antigens released by pulsed electric fields is uncertain. In experiments <italic>in vitro</italic>, IRE, despite releasing the highest amount of protein, which could be due to membrane rupture, was present with 40% denatured proteins, possibly related to the interactions of the high electric field, the charged amino acid residues of proteins, and solvent molecules. Alterations in the secondary structure of proteins are essential for APC processing and antigen presentation (<xref ref-type="bibr" rid="B69">69</xref>). Future <italic>in vivo</italic> experiments are still needed to evaluate the antigenic characteristics of IRE or nsPEF release, which will be important to optimize its stimulation of APC and thus the initiation and activation of T cells.</p>
</list-item>
<list-item>
<p>The effect of IRE on microvasculature remains controversial. A study found that CD31 was increased at 7 days after IRE (1000&#xa0;V; 100 ms; 1&#xa0;Hz; 80 pulses) in the tumor area (<xref ref-type="bibr" rid="B46">46</xref>), but some studies found that CD31 was increased on day 4 after IRE (200 V/960&#xa0;V, 100 us, 1&#xa0;Hz, 20 pulses) but fell back at day 7 (<xref ref-type="bibr" rid="B36">36</xref>). The difference in parameters does not seem to explain this. What is certain, however, is that IRE does preserve local vascular structures better than other thermal ablations, and in the study by Bulvik et&#xa0;al. there was an observed infiltration of inflammatory cells around the vessels, which was not seen with radiofrequency ablation (<xref ref-type="bibr" rid="B73">73</xref>). Therefore, it is important to clarify whether IRE is able to create a time window with the right number of microvessels and increased permeability, as this could provide more support for the timing of combined immunotherapy.</p>
</list-item>
<list-item>
<p>The effect of IRE on immunomodulatory activity has become an area of intensive research. However, most previous studies have provided only some descriptive data on temporal level changes in immune cells. Less has been explored regarding the precise IRE-mediated immune response.</p>
</list-item>
<list-item>
<p>Energy-based local therapies and immunotherapy can be synergistically combined is also a future direction. Pulsed electric fields can promote antigen preservation and local inflammation, and synergistic effects exist between them and immunotherapy (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B66">66</xref>&#x2013;<xref ref-type="bibr" rid="B68">68</xref>).</p>
</list-item>
</list>
</sec>
<sec id="s6">
<title>Conclusion</title>
<p>High voltage electrical pulses&#xa0;cause changes in multiple intracellular signaling pathways to inhibit replication and proliferation of tumor cells, and also kill tumor cells through multiple modes of death by necrosis, pyroptosis, and necroptosis. Pulsed electric fields can contribute to immunogenic death, increase tumor immunogenicity, reverse the immune tolerance environment, and can promote activation and proliferation of cancer-specific cytotoxic T cells acting locally and systemically.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>Study concept and design, YW. Acquisition of data, YW, LTX, HW, JZ, LX, CF, and TJ. Writing-Original draft preparation, YW. Visualization, YW. Obtaining of funding, TJ. Technical or material support, LTX, HW, and TJ. Study supervision, TJ. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>This study was supported by Development Project of National Major Scientific Research Instrument (82027803), National Natural Science Foundation of China (81971623), and Key Project of Natural Science Foundation of Zhejiang Province (LZ20H180001).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivey</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Bonakdar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kanitkar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Davalos</surname> <given-names>RV</given-names>
</name>
<name>
<surname>Verbridge</surname> <given-names>SS</given-names>
</name>
</person-group>. <article-title>Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment</article-title>. <source>Cancer Lett</source> (<year>2016</year>) <volume>380</volume>(<issue>1</issue>):<page-range>330&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donlon</surname> <given-names>NE</given-names>
</name>
<name>
<surname>Power</surname> <given-names>R</given-names>
</name>
<name>
<surname>Hayes</surname> <given-names>C</given-names>
</name>
<name>
<surname>Reynolds</surname> <given-names>JV</given-names>
</name>
<name>
<surname>Lysaght</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity</article-title>. <source>Cancer Lett</source> (<year>2021</year>) <volume>502</volume>:<fpage>84</fpage>&#x2013;<lpage>96</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2020.12.045</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname> <given-names>KF</given-names>
</name>
<name>
<surname>Dupuy</surname> <given-names>DE</given-names>
</name>
</person-group>. <article-title>Thermal ablation of tumours: biological mechanisms and advances in therapy</article-title>. <source>Nat Rev Cancer</source> (<year>2014</year>) <volume>14</volume>(<issue>3</issue>):<fpage>199</fpage>&#x2013;<lpage>208</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrc3672</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batista Napotnik</surname> <given-names>T</given-names>
</name>
<name>
<surname>Polaj&#x17e;er</surname> <given-names>T</given-names>
</name>
<name>
<surname>Miklav&#x10d;i&#x10d;</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Cell death due to electroporation - a review</article-title>. <source>Bioelectrochemistry</source> (<year>2021</year>) <volume>141</volume>:<elocation-id>107871</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bioelechem.2021.107871</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gowrishankar</surname> <given-names>TR</given-names>
</name>
<name>
<surname>Esser</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>KC</given-names>
</name>
<name>
<surname>Son</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Weaver</surname> <given-names>JC</given-names>
</name>
</person-group>. <article-title>Intracellular electroporation site distributions: modeling examples for nsPEF and IRE pulse waveforms</article-title>. <source>Annu Int Conf IEEE Eng Med Biol Soc</source> (<year>2011</year>) <volume>2011</volume>:<page-range>732&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1109/IEMBS.2011.6090166</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Lorenzo</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Arena</surname> <given-names>CB</given-names>
</name>
<name>
<surname>Davalos</surname> <given-names>RV</given-names>
</name>
</person-group>. <article-title>Maximizing local access to therapeutic deliveries in glioblastoma</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>De Vleeschouwer</surname> <given-names>S</given-names>
</name>
</person-group>, editor. <source>Part III: Irreversible electroporation and high-frequency irreversible electroporation for the eradication of glioblastoma</source>. <publisher-loc>Brisbane (AU</publisher-loc>: <publisher-name>Codon Publications</publisher-name> (<year>2017</year>). Chapter 19.</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutter</surname> <given-names>O</given-names>
</name>
<name>
<surname>Calvo</surname> <given-names>J</given-names>
</name>
<name>
<surname>N'Kontchou</surname> <given-names>G</given-names>
</name>
<name>
<surname>Nault</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Ourabia</surname> <given-names>R</given-names>
</name>
<name>
<surname>Nahon</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: A retrospective single-center case series</article-title>. <source>Radiology</source> (<year>2017</year>) <volume>284</volume>(<issue>3</issue>):<page-range>877&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.2017161413</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomson</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>W</given-names>
</name>
<name>
<surname>Ellis</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Federman</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kavnoudias</surname> <given-names>H</given-names>
</name>
<name>
<surname>Loader-Oliver</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Investigation of the safety of irreversible electroporation in humans</article-title>. <source>J Vasc Interv Radiol</source> (<year>2011</year>) <volume>22</volume>(<issue>5</issue>):<page-range>611&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jvir.2010.12.014</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayanan</surname> <given-names>G</given-names>
</name>
<name>
<surname>Bhatia</surname> <given-names>S</given-names>
</name>
<name>
<surname>Echenique</surname> <given-names>A</given-names>
</name>
<name>
<surname>Suthar</surname> <given-names>R</given-names>
</name>
<name>
<surname>Barbery</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yrizarry</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Vessel patency post irreversible electroporation</article-title>. <source>Cardiovasc Intervent Radiol</source> (<year>2014</year>) <volume>37</volume>(<issue>6</issue>):<page-range>1523&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00270-014-0988-9</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>K</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Irreversible electroporation induces CD8+ T cell immune response against post-ablation hepatocellular carcinoma growth</article-title>. <source>Cancer Lett</source> (<year>2021</year>) <volume>503</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2021.01.001</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer</article-title>. <source>Cancer Lett</source> (<year>2021</year>) <volume>502</volume>:<fpage>9</fpage>&#x2013;<lpage>24</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2020.12.018</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polajzer</surname> <given-names>T</given-names>
</name>
<name>
<surname>Jarm</surname> <given-names>T</given-names>
</name>
<name>
<surname>Miklavcic</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Analysis of damage-associated molecular pattern molecules due to electroporation of cells <italic>in vitro</italic>
</article-title>. <source>Radiol Oncol</source> (<year>2020</year>) <volume>54</volume>(<issue>3</issue>):<page-range>317&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2478/raon-2020-0047</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hofmann</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ohnimus</surname> <given-names>H</given-names>
</name>
<name>
<surname>Scheller</surname> <given-names>C</given-names>
</name>
<name>
<surname>Strupp</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zimmermann</surname> <given-names>U</given-names>
</name>
<name>
<surname>Jassoy</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Electric field pulses can induce apoptosis</article-title>. <source>J Membr Biol</source> (<year>1999</year>) <volume>169</volume>(<issue>2</issue>):<page-range>103&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s002329900522</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beebe</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>YJ</given-names>
</name>
<name>
<surname>Sain</surname> <given-names>NM</given-names>
</name>
<name>
<surname>Schoenbach</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Transient features in nanosecond pulsed electric fields differentially modulate mitochondria and viability</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>(<issue>12</issue>):<elocation-id>e51349</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0051349</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>HB</given-names>
</name>
<name>
<surname>Sung</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Baik</surname> <given-names>KY</given-names>
</name>
<name>
<surname>Moon</surname> <given-names>KW</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Changes of apoptosis in tumor tissues with time after irreversible electroporation</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2013</year>) <volume>435</volume>(<issue>4</issue>):<page-range>651&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2013.05.039</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lyu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>TT</given-names>
</name>
<name>
<surname>Rubinsky</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Molecular and histological study on the effects of non-thermal irreversible electroporation on the liver</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2018</year>) <volume>500</volume>(<issue>3</issue>):<page-range>665&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2018.04.132</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldberg</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rubinsky</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>The effect of electroporation type pulsed electric fields on DNA in aqueous solution</article-title>. <source>Technol Cancer Res Treat</source> (<year>2010</year>) <volume>9</volume>(<issue>4</issue>):<page-range>423&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/153303461000900412</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname> <given-names>EH</given-names>
</name>
<name>
<surname>Schoenbach</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Beebe</surname> <given-names>SJ</given-names>
</name>
</person-group>. <article-title>Nanosecond pulsed electric fields induce apoptosis in p53-wildtype and p53-null HCT116 colon carcinoma cells</article-title>. <source>Apoptosis</source> (<year>2007</year>) <volume>12</volume>(<issue>9</issue>):<page-range>1721&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10495-007-0083-7</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szlasa</surname> <given-names>W</given-names>
</name>
<name>
<surname>Kie&#x142;bik</surname> <given-names>A</given-names>
</name>
<name>
<surname>Szewczyk</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rembia&#x142;kowska</surname> <given-names>N</given-names>
</name>
<name>
<surname>Novickij</surname> <given-names>V</given-names>
</name>
<name>
<surname>Tarek</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Oxidative effects during irreversible electroporation of melanoma cells-<italic>In vitro</italic> study</article-title>. <source>Molecules</source> (<year>2020</year>) <volume>26</volume>(<issue>1</issue>):<elocation-id>154</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/molecules26010154</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batista Napotnik</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Gundersen</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Miklav&#x10d;i&#x10d;</surname> <given-names>D</given-names>
</name>
<name>
<surname>Vernier</surname> <given-names>PT</given-names>
</name>
</person-group>. <article-title>Nanosecond electric pulses cause mitochondrial membrane permeabilization in jurkat cells</article-title>. <source>Bioelectromagnetics</source> (<year>2012</year>) <volume>33</volume>(<issue>3</issue>):<page-range>257&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/bem.20707</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>G</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Nanosecond pulsed electric field inhibits cancer growth followed by alteration in expressions of NF-&#x3ba;B and wnt/&#x3b2;-catenin signaling molecules</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>(<issue>9</issue>):<elocation-id>e74322</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0074322</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnamurthy</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kurzrock</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Targeting the wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors</article-title>. <source>Cancer Treat Rev</source> (<year>2018</year>) <volume>62</volume>:<fpage>50</fpage>&#x2013;<lpage>60</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ctrv.2017.11.002</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brock</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Beitel-White</surname> <given-names>N</given-names>
</name>
<name>
<surname>Coutermarsh-Ott</surname> <given-names>S</given-names>
</name>
<name>
<surname>Grider</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Lorenzo</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Ringel-Scaia</surname> <given-names>VM</given-names>
</name>
<etal/>
</person-group>. <article-title>Patient derived xenografts expand human primary pancreatic tumor tissue availability for ex vivo irreversible electroporation testing</article-title>. <source>Front Oncol</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>843</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2020.00843</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname> <given-names>G</given-names>
</name>
<name>
<surname>Guan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Immunomodulatory effect of irreversible electroporation alone and its cooperating with immunotherapy in pancreatic cancer</article-title>. <source>Front Oncol</source> (<year>2021</year>) <volume>11</volume>:<elocation-id>712042</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2021.712042</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>WG</given-names>
</name>
<name>
<surname>Weissberg</surname> <given-names>J</given-names>
</name>
<name>
<surname>Goff</surname> <given-names>CB</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W</given-names>
</name>
<name>
<surname>Kuwayama</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Cutaneous papilloma and squamous cell carcinoma therapy utilizing nanosecond pulsed electric fields (nsPEF)</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>(<issue>8</issue>):<elocation-id>e43891</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0043891</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beebe</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Fox</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Rec</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Willis</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Schoenbach</surname> <given-names>KH</given-names>
</name>
</person-group>. <article-title>Nanosecond, high-intensity pulsed electric fields induce apoptosis in human cells</article-title>. <source>FASEB J</source> (<year>2003</year>) <volume>17</volume>(<issue>11</issue>):<page-range>1493&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1096/fj.02-0859fje</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ringel-Scaia</surname> <given-names>VM</given-names>
</name>
<name>
<surname>Beitel-White</surname> <given-names>N</given-names>
</name>
<name>
<surname>Lorenzo</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Brock</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Huie</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Coutermarsh-Ott</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity</article-title>. <source>EBioMedicine</source> (<year>2019</year>) <volume>44</volume>:<page-range>112&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ebiom.2019.05.036</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>H</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>H</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>High-voltage pulsed electric field plus photodynamic therapy kills breast cancer cells by triggering apoptosis</article-title>. <source>Am J Transl Res</source> (<year>2018</year>) <volume>10</volume>(<issue>2</issue>):<page-range>334&#x2013;51</page-range>.</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>C</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The role of irreversible electroporation in promoting M1 macrophage polarization <italic>via</italic> regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer</article-title>. <source>Oncoimmunology</source> (<year>2021</year>) <volume>10</volume>(<issue>1</issue>):<elocation-id>1897295</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/2162402X.2021.1897295</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brock</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Beitel-White</surname> <given-names>N</given-names>
</name>
<name>
<surname>Davalos</surname> <given-names>RV</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>IC</given-names>
</name>
</person-group>. <article-title>Starting a fire without flame: The induction of cell death and inflammation in electroporation-based tumor ablation strategies</article-title>. <source>Front Oncol</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>1235</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2020.01235</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Procissi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tyler</surname> <given-names>P</given-names>
</name>
<name>
<surname>Omary</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Larson</surname> <given-names>AC</given-names>
</name>
</person-group>. <article-title>Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation</article-title>. <source>Nanomedicine (Lond)</source> (<year>2014</year>) <volume>9</volume>(<issue>8</issue>):<page-range>1181&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2217/nnm.13.72</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#xf3;pez-Alonso</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hern&#xe1;ez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sarnago</surname> <given-names>H</given-names>
</name>
<name>
<surname>Naval</surname> <given-names>A</given-names>
</name>
<name>
<surname>G&#xfc;emes</surname> <given-names>A</given-names>
</name>
<name>
<surname>Junquera</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Histopathological and ultrastructural changes after electroporation in pig liver using parallel-plate electrodes and high-performance generator</article-title>. <source>Sci Rep</source> (<year>2019</year>) <volume>9</volume>(<issue>1</issue>):<fpage>2647</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-019-39433-6</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Low voltage irreversible electroporation induced apoptosis in HeLa cells</article-title>. <source>J Cancer Res Ther</source> (<year>2012</year>) <volume>8</volume>(<issue>1</issue>):<page-range>80&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4103/0973-1482.95179</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faroja</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ahmed</surname> <given-names>M</given-names>
</name>
<name>
<surname>Appelbaum</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ben-David</surname> <given-names>E</given-names>
</name>
<name>
<surname>Moussa</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sosna</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Irreversible electroporation ablation: is all the damage nonthermal</article-title>? <source>Radiology</source> (<year>2013</year>) <volume>266</volume>(<issue>2</issue>):<page-range>462&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.12120609</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Immunogenic cell death in cancer therapy</article-title>. <source>Annu Rev Immunol</source> (<year>2013</year>) <volume>31</volume>:<fpage>51</fpage>&#x2013;<lpage>72</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-100008</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>T</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer</article-title>. <source>Nat Commun</source> (<year>2019</year>) <volume>10</volume>(<issue>1</issue>):<fpage>899</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-019-08782-1</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Eresen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shangguan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Yaghmai</surname> <given-names>V</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer</article-title>. <source>Oncoimmunology</source> (<year>2021</year>) <volume>10</volume>(<issue>1</issue>):<elocation-id>1875638</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/2162402X.2021.1875638</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Go</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chon</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ryu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>DH</given-names>
</name>
<etal/>
</person-group>. <article-title>Combination of irreversible electroporation and STING agonist for effective cancer immunotherapy</article-title>. <source>Cancers (Basel)</source> (<year>2020</year>) <volume>12</volume>(<issue>11</issue>):<elocation-id>3123</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers12113123</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pakhomova</surname> <given-names>ON</given-names>
</name>
<name>
<surname>Mollica</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Casciola</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mangalanathan</surname> <given-names>U</given-names>
</name>
<name>
<surname>Pakhomov</surname> <given-names>AG</given-names>
</name>
<etal/>
</person-group>. <article-title>Nanosecond pulsed electric fields induce endoplasmic reticulum stress accompanied by immunogenic cell death in murine models of lymphoma and colorectal cancer</article-title>. <source>Cancers (Basel)</source> (<year>2019</year>) <volume>11</volume>(<issue>12</issue>):<elocation-id>2034</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers11122034</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pawaria</surname> <given-names>S</given-names>
</name>
<name>
<surname>Binder</surname> <given-names>RJ</given-names>
</name>
</person-group>. <article-title>CD91-dependent programming of T-helper cell responses following heat shock protein immunization</article-title>. <source>Nat Commun</source> (<year>2011</year>) <volume>2</volume>:<fpage>521</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ncomms1524</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messmer</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Telusma</surname> <given-names>G</given-names>
</name>
<name>
<surname>Knoll</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Messmer</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>173</volume>(<issue>1</issue>):<page-range>307&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.173.1.307</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumitriu</surname> <given-names>IE</given-names>
</name>
<name>
<surname>Baruah</surname> <given-names>P</given-names>
</name>
<name>
<surname>Valentinis</surname> <given-names>B</given-names>
</name>
<name>
<surname>Voll</surname> <given-names>RE</given-names>
</name>
<name>
<surname>Herrmann</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nawroth</surname> <given-names>PP</given-names>
</name>
<etal/>
</person-group>. <article-title>Release of high mobility group box 1 by dendritic cells controls T cell activation <italic>via</italic> the receptor for advanced glycation end products</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>174</volume>(<issue>12</issue>):<page-range>7506&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.174.12.7506</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orlova</surname> <given-names>VV</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>EY</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chavakis</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bierhaus</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ihanus</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires mac-1-integrin</article-title>. <source>EMBO J</source> (<year>2007</year>) <volume>26</volume>(<issue>4</issue>):<page-range>1129&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/sj.emboj.7601552</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapouri-Moghaddam</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mohammadian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vazini</surname> <given-names>H</given-names>
</name>
<name>
<surname>Taghadosi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Esmaeili</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Mardani</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage plasticity, polarization, and function in health and disease</article-title>. <source>J Cell Physiol</source> (<year>2018</year>) <volume>233</volume>(<issue>9</issue>):<page-range>6425&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcp.26429</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantovani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sozzani</surname> <given-names>S</given-names>
</name>
<name>
<surname>Locati</surname> <given-names>M</given-names>
</name>
<name>
<surname>Allavena</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sica</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes</article-title>. <source>Trends Immunol</source> (<year>2002</year>) <volume>23</volume>(<issue>11</issue>):<page-range>549&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s1471-4906(02)02302-5</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>C</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>T-Cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer</article-title>. <source>Clin Transl Med</source> (<year>2020</year>) <volume>10</volume>(<issue>2</issue>):<elocation-id>e39</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ctm2.39</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Au</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Mittra</surname> <given-names>A</given-names>
</name>
<name>
<surname>Song</surname> <given-names>TJ</given-names>
</name>
<name>
<surname>Cavnar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jun</surname> <given-names>K</given-names>
</name>
<name>
<surname>Carson</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response</article-title>. <source>Surgery</source> (<year>2013</year>) <volume>154</volume>(<issue>3</issue>):<fpage>496</fpage>&#x2013;<lpage>503</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.surg.2013.06.005</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Saxena</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bhardwaj</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Dendritic cell subsets and locations</article-title>. <source>Int Rev Cell Mol Biol</source> (<year>2019</year>) <volume>348</volume>:<fpage>1</fpage>&#x2013;<lpage>68</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/bs.ircmb.2019.07.004</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alnaggar</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mesmar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Qaid</surname> <given-names>A</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Allogenic natural killer cell immunotherapy combined with irreversible electroporation for stage IV hepatocellular carcinoma: Survival outcome</article-title>. <source>Cell Physiol Biochem</source> (<year>2018</year>) <volume>48</volume>(<issue>5</issue>):<page-range>1882&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000492509</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Immunomodulatory effect after irreversible electroporation in patients with locally advanced pancreatic cancer</article-title>. <source>J Oncol</source> (<year>2019</year>) <volume>2019</volume>:<elocation-id>9346017</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/9346017</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>The local liver ablation with pulsed electric field stimulate systemic immune reaction against HCC with time-dependent cytokine profile</article-title>. <source>Cytokine</source> (<year>2017</year>) <volume>93</volume>:<fpage>44</fpage>&#x2013;<lpage>50</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cyto.2017.05.003</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borish</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Steinke</surname> <given-names>JW</given-names>
</name>
</person-group>. <article-title>2. cytokines and chemokines</article-title>. <source>J Allergy Clin Immunol</source> (<year>2003</year>) <volume>111</volume>(<supplement>2 Suppl</supplement>):<page-range>S460&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1067/mai.2003.108</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Antitumor effect and immune response of nanosecond pulsed electric fields in pancreatic cancer</article-title>. <source>Front Oncol</source> (<year>2021</year>) <volume>10</volume>:<elocation-id>621092</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2020.621092</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>B</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunologic response to tumor ablation with irreversible electroporation</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>(<issue>11</issue>):<elocation-id>e48749</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0048749</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonilla</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Oettgen</surname> <given-names>HC</given-names>
</name>
</person-group>. <article-title>Adaptive immunity</article-title>. <source>J Allergy Clin Immunol</source> (<year>2010</year>) <volume>125</volume>(<supplement>2 Suppl 2</supplement>):<page-range>S33&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.017</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yimingjiang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tuergan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparative analysis of immunoactivation by nanosecond pulsed electric fields and PD-1 blockade in murine hepatocellular carcinoma</article-title>. <source>Anal Cell Pathol (Amst)</source> (<year>2020</year>) <volume>2020</volume>:<elocation-id>9582731</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2020/9582731</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teicher</surname> <given-names>BA</given-names>
</name>
</person-group>. <article-title>Transforming growth factor-beta and the immune response to malignant disease</article-title>. <source>Clin Cancer Res</source> (<year>2007</year>) <volume>13</volume>(<issue>21</issue>):<page-range>6247&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1654</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakaguchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yamaguchi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nomura</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ono</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Regulatory T cells and immune tolerance</article-title>. <source>Cell</source> (<year>2008</year>) <volume>133</volume>(<issue>5</issue>):<page-range>775&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2008.05.009</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petersen</surname> <given-names>RP</given-names>
</name>
<name>
<surname>Campa</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Sperlazza</surname> <given-names>J</given-names>
</name>
<name>
<surname>Conlon</surname> <given-names>D</given-names>
</name>
<name>
<surname>Joshi</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Harpole</surname> <given-names>DH</given-names>
<suffix>Jr</suffix>
</name>
<etal/>
</person-group>. <article-title>Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients</article-title>. <source>Cancer</source> (<year>2006</year>) <volume>107</volume>(<issue>12</issue>):<page-range>2866&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cncr.22282</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whiteside</surname> <given-names>TL</given-names>
</name>
</person-group>. <article-title>FOXP3+ treg as a therapeutic target for promoting anti-tumor immunity</article-title>. <source>Expert Opin Ther Targets</source> (<year>2018</year>) <volume>22</volume>(<issue>4</issue>):<page-range>353&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/14728222.2018.1451514</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassetta</surname> <given-names>L</given-names>
</name>
<name>
<surname>Pollard</surname> <given-names>JW</given-names>
</name>
</person-group>. <article-title>Tumor-associated macrophages</article-title>. <source>Curr Biol</source> (<year>2020</year>) <volume>30</volume>(<issue>6</issue>):<page-range>R246&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cub.2020.01.031</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname> <given-names>V</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tcyganov</surname> <given-names>E</given-names>
</name>
<name>
<surname>Gabrilovich</surname> <given-names>DI</given-names>
</name>
</person-group>. <article-title>The nature of myeloid-derived suppressor cells in the tumor microenvironment</article-title>. <source>Trends Immunol</source> (<year>2016</year>) <volume>37</volume>(<issue>3</issue>):<page-range>208&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2016.01.004</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belli</surname> <given-names>C</given-names>
</name>
<name>
<surname>Trapani</surname> <given-names>D</given-names>
</name>
<name>
<surname>Viale</surname> <given-names>G</given-names>
</name>
<name>
<surname>D'Amico</surname> <given-names>P</given-names>
</name>
<name>
<surname>Duso</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Della Vigna</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting the microenvironment in solid tumors</article-title>. <source>Cancer Treat Rev</source> (<year>2018</year>) <volume>65</volume>:<fpage>22</fpage>&#x2013;<lpage>32</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ctrv.2018.02.004</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheffer</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Stam</surname> <given-names>AGM</given-names>
</name>
<name>
<surname>Geboers</surname> <given-names>B</given-names>
</name>
<name>
<surname>Vroomen</surname> <given-names>LGPH</given-names>
</name>
<name>
<surname>Ruarus</surname> <given-names>A</given-names>
</name>
<name>
<surname>de Bruijn</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation</article-title>. <source>Oncoimmunology</source> (<year>2019</year>) <volume>8</volume>(<issue>11</issue>):<elocation-id>1652532</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/2162402X.2019.1652532</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandit</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>YK</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Rostas</surname> <given-names>J</given-names>
</name>
<name>
<surname>Pulliam</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>SP</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluating the regulatory immunomodulation effect of irreversible electroporation (IRE) in pancreatic adenocarcinoma</article-title>. <source>Ann Surg Oncol</source> (<year>2019</year>) <volume>26</volume>(<issue>3</issue>):<page-range>800&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1245/s10434-018-07144-3</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>QW</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>XX</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>QB</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>ZY</given-names>
</name>
<etal/>
</person-group>. <article-title>OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model</article-title>. <source>Am J Cancer Res</source> (<year>2021</year>) <volume>11</volume>(<issue>6</issue>):<page-range>2782&#x2013;801</page-range>.</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Nanosecond pulsed electric field inhibits malignant melanoma growth by inducing the change of systemic immunity</article-title>. <source>Med Oral Patol Oral Cir Bucal</source> (<year>2019</year>) <volume>24</volume>(<issue>4</issue>):<page-range>e555&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4317/medoral.22976</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burbach</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>O'Flanagan</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Young</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Slaughter</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Rollins</surname> <given-names>MR</given-names>
</name>
<etal/>
</person-group>. <article-title>Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>(<issue>1</issue>):<fpage>3862</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-021-24132-6</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gogineni</surname> <given-names>VR</given-names>
</name>
<name>
<surname>Larson</surname> <given-names>AC</given-names>
</name>
</person-group>. <article-title>Early immunologic response of irreversible electroporation versus cryoablation in a rodent model of pancreatic cancer</article-title>. <source>J Vasc Interv Radiol</source> (<year>2018</year>) <volume>29</volume>(<issue>12</issue>):<page-range>1764&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jvir.2018.07.009</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>X</given-names>
</name>
<name>
<surname>O'Neill</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Irreversible electroporation enhances immunotherapeutic effect in the off-target tumor in a murine model of orthotopic HCC</article-title>. <source>Am J Cancer Res</source> (<year>2021</year>) <volume>11</volume>(<issue>6</issue>):<page-range>3304&#x2013;19</page-range>.</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellman</surname> <given-names>I</given-names>
</name>
<name>
<surname>Coukos</surname> <given-names>G</given-names>
</name>
<name>
<surname>Dranoff</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Cancer immunotherapy comes of age</article-title>. <source>Nature</source> (<year>2011</year>) <volume>480</volume>(<issue>7378</issue>):<page-range>480&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature10673</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babikr</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ahmed</surname> <given-names>S</given-names>
</name>
<name>
<surname>Freywald</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors</article-title>. <source>Cell Mol Immunol</source> (<year>2021</year>) <volume>18</volume>(<issue>12</issue>):<page-range>2632&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41423-021-00796-4</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bulvik</surname> <given-names>BE</given-names>
</name>
<name>
<surname>Rozenblum</surname> <given-names>N</given-names>
</name>
<name>
<surname>Gourevich</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ahmed</surname> <given-names>M</given-names>
</name>
<name>
<surname>Andriyanov</surname> <given-names>AV</given-names>
</name>
<name>
<surname>Galun</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Irreversible electroporation versus radiofrequency ablation: A comparison of local and systemic effects in a small-animal model</article-title>. <source>Radiology</source> (<year>2016</year>) <volume>280</volume>(<issue>2</issue>):<page-range>413&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1148/radiol.2015151166</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maor</surname> <given-names>E</given-names>
</name>
<name>
<surname>Rubinsky</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Nonthermal irreversible electroporation for tissue decellularization</article-title>. <source>J Biomech Eng</source> (<year>2010</year>) <volume>132</volume>(<issue>9</issue>):<fpage>091003</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1115/1.4001882</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>YJ</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>DS</given-names>
</name>
<name>
<surname>Osuagwu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Lassman</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Irreversible electroporation in porcine liver: acute computed tomography appearance of ablation zone with histopathologic correlation</article-title>. <source>J Comput Assist Tomogr</source> (<year>2013</year>) <volume>37</volume>(<issue>2</issue>):<page-range>154&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/RCT.0b013e31827dbf9b</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname> <given-names>G</given-names>
</name>
<name>
<surname>Bakos</surname> <given-names>G</given-names>
</name>
<name>
<surname>Shires</surname> <given-names>PK</given-names>
</name>
<name>
<surname>Gritter</surname> <given-names>L</given-names>
</name>
<name>
<surname>Crissman</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Histological and finite element analysis of cell death due to irreversible electroporation</article-title>. <source>Technol Cancer Res Treat</source> (<year>2014</year>) <volume>13</volume>(<issue>6</issue>):<page-range>561&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7785/tcrtexpress.2013.600253</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Rubinsky</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Molecular and histological study on the effects of electrolytic electroporation on the liver</article-title>. <source>Bioelectrochemistry</source> (<year>2019</year>) <volume>125</volume>:<fpage>79</fpage>&#x2013;<lpage>89</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bioelechem.2018.09.007</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tonini</surname> <given-names>T</given-names>
</name>
<name>
<surname>Rossi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Claudio</surname> <given-names>PP</given-names>
</name>
</person-group>. <article-title>Molecular basis of angiogenesis and cancer</article-title>. <source>Oncogene</source> (<year>2003</year>) <volume>22</volume>(<issue>42</issue>):<page-range>6549&#x2013;56</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/sj.onc.1206816</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carmeliet</surname> <given-names>P</given-names>
</name>
<name>
<surname>Jain</surname> <given-names>RK</given-names>
</name>
</person-group>. <article-title>Angiogenesis in cancer and other diseases</article-title>. <source>Nature</source> (<year>2000</year>) <volume>407</volume>(<issue>6801</issue>):<page-range>249&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/35025220</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nasarre</surname> <given-names>P</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kruse</surname> <given-names>K</given-names>
</name>
<name>
<surname>Helfrich</surname> <given-names>I</given-names>
</name>
<name>
<surname>Wolter</surname> <given-names>V</given-names>
</name>
<name>
<surname>Deppermann</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>(<issue>4</issue>):<page-range>1324&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3030</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahma</surname> <given-names>OE</given-names>
</name>
<name>
<surname>Hodi</surname> <given-names>FS</given-names>
</name>
</person-group>. <article-title>The intersection between tumor angiogenesis and immune suppression</article-title>. <source>Clin Cancer Res</source> (<year>2019</year>) <volume>25</volume>(<issue>18</issue>):<page-range>5449&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1543</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oyama</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ran</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ishida</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nadaf</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kerr</surname> <given-names>L</given-names>
</name>
<name>
<surname>Carbone</surname> <given-names>DP</given-names>
</name>
<etal/>
</person-group>. <article-title>Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa b activation in hemopoietic progenitor cells</article-title>. <source>J Immunol</source> (<year>1998</year>) <volume>160</volume>(<issue>3</issue>):<page-range>1224&#x2013;32</page-range>.</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohm</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Gabrilovich</surname> <given-names>DI</given-names>
</name>
<name>
<surname>Sempowski</surname> <given-names>GD</given-names>
</name>
<name>
<surname>Kisseleva</surname> <given-names>E</given-names>
</name>
<name>
<surname>Parman</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Nadaf</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression</article-title>. <source>Blood</source> (<year>2003</year>) <volume>101</volume>(<issue>12</issue>):<page-range>4878&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2002-07-1956</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wada</surname> <given-names>J</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fuchino</surname> <given-names>R</given-names>
</name>
<name>
<surname>Yamasaki</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nagai</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yanai</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions</article-title>. <source>Anticancer Res</source> (<year>2009</year>) <volume>29</volume>(<issue>3</issue>):<page-range>881&#x2013;8</page-range>.</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chi</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Si</surname> <given-names>L</given-names>
</name>
<name>
<surname>Sheng</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Nanosecond pulsed electric fields enhance the anti-tumour effects of the mTOR inhibitor everolimus against melanoma</article-title>. <source>Sci Rep</source> (<year>2017</year>) <volume>7</volume>:<elocation-id>39597</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep39597</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hofmeister</surname> <given-names>V</given-names>
</name>
<name>
<surname>Vetter</surname> <given-names>C</given-names>
</name>
<name>
<surname>Schrama</surname> <given-names>D</given-names>
</name>
<name>
<surname>Br&#xf6;cker</surname> <given-names>EB</given-names>
</name>
<name>
<surname>Becker</surname> <given-names>JC</given-names>
</name>
</person-group>. <article-title>Tumor stroma-associated antigens for anti-cancer immunotherapy</article-title>. <source>Cancer Immunol Immunother</source> (<year>2006</year>) <volume>55</volume>(<issue>5</issue>):<page-range>481&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/bioe.2021.0014</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujimori</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kimura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ueshima</surname> <given-names>E</given-names>
</name>
<name>
<surname>Dupuy</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Adusumilli</surname> <given-names>PS</given-names>
</name>
<name>
<surname>Solomon</surname> <given-names>SB</given-names>
</name>
<etal/>
</person-group>. <article-title>Lung ablation with irreversible electroporation promotes immune cell infiltration by sparing extracellular matrix proteins and vasculature: Implications for immunotherapy</article-title>. <source>Bioelectricity</source> (<year>2021</year>) <volume>3</volume>(<issue>3</issue>):<page-range>204&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/bioe.2021.0014</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doedens</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Stockmann</surname> <given-names>C</given-names>
</name>
<name>
<surname>Rubinstein</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>DeNardo</surname> <given-names>DG</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>(<issue>19</issue>):<page-range>7465&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1439</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brand</surname> <given-names>A</given-names>
</name>
<name>
<surname>Singer</surname> <given-names>K</given-names>
</name>
<name>
<surname>Koehl</surname> <given-names>GE</given-names>
</name>
<name>
<surname>Kolitzus</surname> <given-names>M</given-names>
</name>
<name>
<surname>Schoenhammer</surname> <given-names>G</given-names>
</name>
<name>
<surname>Thiel</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells</article-title>. <source>Cell Metab</source> (<year>2016</year>) <volume>24</volume>(<issue>5</issue>):<page-range>657&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.011</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoenbach</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Joshi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kolb</surname> <given-names>J</given-names>
</name>
<name>
<surname>Buescher</surname> <given-names>S</given-names>
</name>
<name>
<surname>Beebe</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Subcellular effects of nanosecond electrical pulses</article-title>. <source>Conf Proc IEEE Eng Med Biol Soc</source> (<year>2004</year>) <volume>2004</volume>:<page-range>5447&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1109/IEMBS.2004.1404522</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breton</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mir</surname> <given-names>LM</given-names>
</name>
</person-group>. <article-title>Microsecond and nanosecond electric pulses in cancer treatments</article-title>. <source>Bioelectromagnetics</source> (<year>2012</year>) <volume>33</volume>(<issue>2</issue>):<page-range>106&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/bem.20692</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sigismund</surname> <given-names>S</given-names>
</name>
<name>
<surname>Avanzato</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lanzetti</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Emerging functions of the EGFR in cancer</article-title>. <source>Mol Oncol</source> (<year>2018</year>) <volume>12</volume>(<issue>1</issue>):<fpage>3</fpage>&#x2013;<lpage>20</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/1878-0261.12155</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drosten</surname> <given-names>M</given-names>
</name>
<name>
<surname>Barbacid</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Targeting the MAPK pathway in KRAS-driven tumors</article-title>. <source>Cancer Cell</source> (<year>2020</year>) <volume>37</volume>(<issue>4</issue>):<page-range>543&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2020.03.013</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>